Dr Reddy’s Laboratories on Wednesday reported a consolidated net profit of R550 crore for Q1FY15, up 52% y-o-y. Total revenue increased 24% y-o-y to R3,518 crore, driven by 32% growth at the global generics business and 51% growth in the US.The company benefited from several launches of limited competition products. It filed nine product filings in the US and 70 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA. During the quarter, the company launched 25 new generic products, filed 27 new product applications and 20 drug master files globally.

Source - http://www.financialexpress.com